Lakefront Biotherapeutics Overview
Lakefront Biotherapeutics is the renamed and restructured Galapagos, once one of Europe's most richly funded biotechs. It is now a capital-rich, business-development-led company building a clinical portfolio in immunology and inflammation. Its anchor asset is gamgertamig (OM336), a subcutaneous BCMAxCD3 bispecific T-cell engager. Lakefront and its 25%-shareholder Gilead Sciences jointly acquired gamgertamig through the June 2026 purchase of Ouro Medicines. Lakefront funds and runs development up to registrational studies, splits registrational costs 50/50 with Gilead, and will receive tiered 20–23% royalties on Gilead's global sales outside KeyMed's Greater China territory. The legacy businesses are gone or nearly gone. Jyseleca (filgotinib) was transferred to Alfasigma in 2024, cell therapy was wound down in 2026 with preclinical assets sold to Armed Cell Therapeutics, and the TYK2 inhibitor GLPG3667 is under strategic review. With ~€2.0bn of cash guided for end-2026, the company trades below cash, which makes it effectively an option on gamgertamig plus a deployable BD war chest. [H1-2026 PR; Mar-31-2026 6-K; Oct-14-2026 PR]
Company's own description (latest). Lakefront describes itself as a biotechnology company building a differentiated pipeline of medicines for serious diseases with high unmet need. It says it has established a clinical-stage immunology and inflammation portfolio anchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3 T-cell engager for autoimmune diseases. It positions itself as combining deal-making expertise, operational flexibility and a strong capital position to identify, acquire and advance high-quality assets [H1-2026 PR, "About Lakefront"]. The FY2025 Form 20-F (filed 26 March 2026, still under the Galapagos name) describes a pivot to a business-development-led model focused on oncology and immunology & inflammation (I&I). Under that model the company applies modality-agnostic asset selection and prioritises programmes with clear clinical proof-of-concept [FY2025 6-K/20-F summaries; Mar-31-2026 PR "About Galapagos"].
Independent characterisation. Economically, Lakefront in late 2026 is three things:
-
A royalty-and-cost-sharing development partner on a single mid-stage asset. On gamgertamig, Lakefront carries 100% of pre-registrational development cost and 50% of registrational cost, while Gilead commercialises. This resembles a structured co-development or royalty-funding vehicle more than a fully integrated biopharma.
-
A cash-rich capital allocator. ~€2.24bn of cash and financial investments sat on the balance sheet at 30 June 2026, guided to ~€1.975–2.05bn at year-end. Management forecasts at least €1.6bn of "dry powder" after funding gamgertamig to first approval [H1-2026 PR].
-
A small residual legacy revenue base. This consists of Jyseleca supply revenue to Alfasigma under a transition agreement, Jyseleca royalties from Gilead, and interest and fair-value income on the treasury portfolio.
Business model and revenue model mix. Revenues are currently non-product:
[H1-2026 PR]
Before 2026, the dominant line was non-cash recognition of the ~€2.3bn contract liability from the 2019 Gilead Option, License & Collaboration Agreement (OLCA), recognised straight-line over 10 years. The remaining €1,069.0M was released in full in FY2025 [FY2025 PR; Q4-2025 call]. Future revenue will depend on (a) gamgertamig royalties of 20–23% on Gilead net sales, which would follow approval and therefore not before roughly 2029–2030 on the stated registrational timing; (b) up to $100M in development milestones from Gilead; (c) Armed Cell milestones (up to $230M) and low-single-digit royalties; and (d) any opt-in payments of $75M per programme should Gilead exercise options on the three in-licensed preclinical programmes [Mar-31-2026 6-K; H1-2026 PR; Oct-14-2026 PR]. Treasury income remains significant: fair-value gains and interest excluding FX totalled €48.6M in H1 2026 [H1-2026 PR].
Value-chain position. Lakefront is a clinical development organisation without manufacturing or commercial infrastructure. Gilead holds global commercialisation outside Greater China, and KeyMed Biosciences (Chengdu) holds Greater China rights and runs its own studies there [H1-2026 PR; Mar-31-2026 6-K].
Customer types and end-markets. The immediate counterparties are partners (Gilead, Alfasigma, KeyMed), not patients or payers. The ultimate end-markets are rare, antibody-mediated autoimmune diseases: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), idiopathic inflammatory myositis, Sjögren's disease, pemphigus vulgaris and foliaceus, and antiphospholipid syndrome (case report). Additional autoimmune basket indications are planned from 2027 [H1-2026 PR; ISTH 2026 poster].
Strategy
Stated strategy themes (FY2025 annual report and 2026 communications).
-
Business-development-led growth. Deploy capital in "transformative" transactions in oncology and I&I, with modality-agnostic selection and a preference for assets with clinical proof-of-concept [FY2025 PR; Mar-31-2026 PR].
-
Disciplined capital allocation. Keep the majority of cash for further deals and capital-allocation priorities, including shareholder returns. The OLCA waiver frees $500M (≈€425M) of cash from Gilead's rights, with up to $150M usable for buybacks or distributions [Mar-31-2026 6-K; Q1-2026 PR].
-
Lean operating model. The cell-therapy exit reduces the core organisation to ~35–40 people plus the acquired Ouro clinical team [FY2025 6-K summary].
-
Build an immunology franchise around gamgertamig. Accelerate and expand development: proof-of-concept basket studies in additional autoimmune indications from 2027 and registrational entry in 2027 [H1-2026 PR].
Initiatives in the last 24 months
Medium-term financial targets and guidance
Products & Services
Lakefront has no marketed products. The catalog below covers every disclosed clinical and preclinical asset, plus divested and legacy products, for completeness.
Immunology & Inflammation (core portfolio)
| Asset | Modality / mechanism | Indications & stage | Rights & economics | Key facts |
|---|---|---|---|---|
| Gamgertamig (OM336) | Subcutaneous BCMAxCD3 bispecific T-cell engager; deep plasma-cell and B-cell depletion after a short treatment course ("immune reset") | Phase 1b in autoimmune cytopenias (ITP, AIHA), NCT07083960, Australia & US. Phase 1b in seropositive autoimmune diseases (myositis, Sjögren's, PV, PF), NCT07229144, Australia, NZ, Czech Republic, Japan. KeyMed-sponsored studies in Greater China in malignant and autoimmune indications. Registrational studies expected 2027 | Lakefront: 100% pre-registrational development costs; 50/50 registrational costs (execution split by indication); 20–23% tiered royalties from Gilead; up to $100M development milestones. Lakefront also funds 25% of KeyMed milestones and 50% of KeyMed royalties (KeyMed entitled to up to $610M milestones and 7–14% royalties) | FDA Fast Track + Orphan Drug (AIHA, ITP); Orphan Drug (pemphigus, Aug 2026). >60 patients across five autoimmune indications at time of deal [Munich Startup/Yahoo summary of Q1 2026]. ISTH 2026 poster in APS + autoimmune thrombocytopenia |
| BCMAxCD19xCD3 trispecific T-cell engager | Trispecific T-cell engager | Preclinical / research stage | Licensed from the Ouro estate for development and commercialisation | Disclosed in the Framework Agreement licensing term sheet [Mar-31-2026 6-K] |
| Three preclinical autoimmune/inflammatory programmes (ex-Ouro) | Undisclosed | Preclinical | Lakefront-owned. Gilead option to opt into a 50/50 profit split after clinical proof-of-concept for $75M per programme | Names not publicly disclosed [H1-2026 PR] |
| GLPG3667 | Oral selective TYK2 inhibitor | Phase 2 GALARISSO (dermatomyositis): 24-week OLE complete, sustained efficacy and consistent safety. Phase 2 GALACELA (SLE): missed 32-week primary endpoint and 48-week secondary endpoint; favourable safety | Wholly owned. Strategic options under evaluation (partnering, out-licence or sale) | ACR 2025 in-vitro data claimed differentiation versus other TYK2s at clinical doses [Q3-2025 PR; H1-2026 PR] |
Oncology / Cell Therapy (wound down or divested)
| Asset | Description | Status |
|---|---|---|
| GLPG5101 | CD19 CAR-T, decentralised point-of-care manufacturing, Phase 1/2 in rrNHL (ATALANTA-1) | Discontinued under the 2026 wind-down. Long-term safety follow-up continues in the HESPERIA study [H1-2026 PR] |
| GLPG5201 | CD19 CAR-T, Phase 1/2 in rrCLL / Richter transformation | Discontinued [roic.ai; H1-2026 PR] |
| GLPG5301 | BCMA CAR-T, Phase 1/2 in rrMM | Discontinued |
| Decentralised manufacturing platform (xCellit® workflow; Cocoon® integration; Landmark Bio point-of-care agreement) | Point-of-care CAR-T production | Wound down; wind-down "substantially completed" targeted by end Q3 2026 [H1-2026 PR] |
| Preclinical multi-targeting and armed CAR-T constructs (AboundBio-derived): two armed CAR-Ts nearing human testing in NHL and small-cell lung cancer, plus three confidential programmes | Next-generation CAR-T | Sold to Armed Cell Therapeutics BV, completed 14 Oct 2026: €8M upfront, up to $230M milestones, low-single-digit royalty [Oct-14-2026 PR; BioPharma Dive] |
Legacy commercial product
| Product | Description | Status |
|---|---|---|
| Jyseleca® (filgotinib) | Oral JAK1-preferential inhibitor for RA and ulcerative colitis (EU/Japan) | Business transferred to Alfasigma (completed early 2024). Lakefront still supplies product under a transition agreement (H1 2026 supply revenue €14.1M) and receives royalties from Gilead (H1 2026 €4.5M) [H1-2026 PR] |
Pricing models. Not applicable, since there are no marketed products. Gamgertamig economics run through royalties as detailed above.
Financial Narrative
Income statement
[FY2021 revenue/operating loss/EBITDA/pre-tax: TipRanks (original basis). FY2021 net loss €109.6M per company FY2021 reporting; TipRanks shows -125.4, a discrepancy flagged. FY2022 revenue as originally reported (TipRanks); FY2022 operating loss and net lines restated per FY2023 PR. FY2023–2024: FY2023 PR, MT Newswires, FY2025 PR. FY2025: FY2025 PR. FY2021 EPS† = -109.6/65.5M shares. FY2025 EPS† = 320.9/~65.9M shares.
Margins
[Derived†. FY2022 operating margin mixes the restated operating loss with originally reported revenue and is shown for continuity only.]
Gross profit. Not meaningful. Aggregator "gross profit" figures (e.g., FY2024 €-94.7M) reflect classification of cost lines rather than a true product gross margin. In H1 2026, cost of sales of €13.9M related solely to Jyseleca supply [TipRanks; H1-2026 PR].
Revenue CAGR. FY2021–FY2025 headline CAGR is +23.1%†, but this is meaningless because FY2025 includes the €1,069.0M non-cash release. Excluding that release, FY2025 revenue is about €43M† and the underlying CAGR is sharply negative.
Interim 2026 (EUR M)
[Q1-2026 PR/transcript; H1-2026 PR]
Balance sheet
[FY2024 €3,317.8M and FY2025 €2,998.0M: FY2025 PR/Q4 call. FY2021–FY2023†: back-derived from reported annual net decreases of €609.1M (2022) and €409.6M (2023) [FY2023 PR]. FY2025 total assets and liabilities from edgar.tools snapshot, labelled "$" but believed to be EUR; currency not confirmed. The company carries no bank or bond debt; lease liabilities only, amounts n/d.]
30 June 2026: Cash and financial investments were €2,239.5M, including $1,962.2M held in USD (≈72% USD exposure after deliberate conversion in early 2026). Non-current assets were €311.7M at 31 Mar 2026 [H1-2026 PR; Q1-2026 PR; Q4-2025 call].
Goodwill and intangibles. Post-Ouro, intangible assets from the acquired licences and operational assets will appear on the balance sheet.
Equity. Roughly €3.2bn at FY2025† (total assets less total liabilities per edgar.tools). Shares outstanding ~65.9M.
Working capital. Not separately disclosed. It is dominated by current financial investments.
Cash flow
[FY2023 PR; FY2024–FY2025 derived† from cash balances.
H1 2026 cash bridge (EUR M) [H1-2026 PR]
Ratios
Commentary on trends, inflections and drivers.
-
Revenue optics versus economics. Since 2019, reported revenue has been dominated by non-cash amortisation of Gilead's 2019 upfront payment. The FY2025 spike to €1.11bn reflects only the acceleration of the remaining €1,069.0M balance once the drug-discovery platform obligations ceased. The company said it expected no cash tax impact [Q4-2025 call]. From 2026, revenue collapses to a run-rate of about €30–40M† (H1 2026: €18.6M), consisting of low-margin supply revenue and royalties.
-
Cost reset. H1 2026 R&D fell 80% year on year to €56.5M and G&A plus S&M fell 22% to €58.0M. H1 2025 carried €131.6M of reorganisation charges, including €47.5M of severance and €45.7M of early collaboration termination costs [H1-2026 PR]. Full-year 2025 also absorbed ~€399.8M of wind-down and restructuring charges, including €228.1M of impairment [MarketBeat Q4 call summary; FY2025 6-K].
-
Profitability is financial, not operating. The H1 2026 net profit of €16.6M rests entirely on €123.2M of net financial income, of which €97.1M came from fair-value and FX gains, set against a €107.2M operating loss [H1-2026 PR]. The 72% USD cash weighting makes reported earnings highly sensitive to EUR/USD.
-
Cash trajectory inflection. Pre-Ouro guidance was €2.775–2.850bn at end-2026, with the business cash-flow neutral to positive by end-2026. After the €733.5M Ouro outlay, the €50M buyback and gamgertamig development spend, guidance moved to €1.975–2.050bn, assuming EUR/USD 1.175 [FY2025 PR; H1-2026 PR]. Gamgertamig's pre-registrational funding commitment means the business will no longer be cash-flow neutral in a steady state. Management frames at least €1.6bn as remaining after funding to first approval.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue Lines
| Revenue line (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total net revenues | 239.7 | 275.6 | 1,112.2 |
of which: Gilead platform deferred-income recognition (regular straight-line) | — | 230.1 | 230.1 |
of which: accelerated release of remaining deferred income | 0 | 0 | 1,069.0 |
Revenue Lines (Half-Yearly)
| Revenue line (EUR Mn) | H1-2025 | H1-2026 | YoY % |
|---|---|---|---|
Supply revenues | 18.5 | 14.1 | -24 |
Collaboration revenues | 121.8 | 4.5 | -96 |
of which Gilead platform recognition | 115.1 | 0 | -100 |
of which Jyseleca royalties | 5.6 | 4.5 | -20 |
Total net revenues | 140.3 | 18.6 | -87 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total net revenues (EUR Mn) | 484.8 | 505.3 | 239.7 | 275.6 | 1,112.2 |
Operating profit/loss (EUR Mn) | -165.6 | -131.1 | -88.3 | -188.3 | 295.1 |
EBITDA (EUR Mn, aggregator) | -100.9 | -33.4 | 51.0 | -152.9 | — |
Pre-tax income (EUR Mn, aggregator) | -123.0 | -215.2 | 5.6 | -3.1 | — |
Net profit/loss continuing ops (EUR Mn) | — | -71.4 | -4.0 | -1.3 | 319.5 |
Net profit/loss discontinued ops (EUR Mn) | — | -146.6 | 215.7 | 75.4 | 1.4 |
Net profit/loss total (EUR Mn) | -109.6 | -218.0 | 211.7 | 74.1 | 320.9 |
Diluted EPS total (EUR) | -1.67 | -3.32 | 3.21 | 1.12 | 4.87 |
Dividends per share (EUR) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating margin (%) | -34.2 | -25.9 | -36.8 | -68.3 | 26.5 |
Net margin (%) | -22.6 | -43.1 | 88.3 | 26.9 | 28.9 |
EBITDA margin (%) | -20.8 | -6.6 | 21.3 | -55.5 | — |
Income Statement and Per-Share Data (Q1-2025–H1-2026)
| Metric | Q1-2025 | Q1-2026 | H1-2025 | H1-2026 |
|---|---|---|---|---|
Total net revenues (EUR Mn) | 75.0 | 6.5 | 140.3 | 18.6 |
R&D expenses (EUR Mn) | -182.7 | -31.0 | -278.0 | -56.5 |
G&A + S&M (EUR Mn) | — | — | -74.5 | -58.0 |
Operating loss (EUR Mn) | — | — | -215.7 | -107.2 |
Net financial result (EUR Mn) | — | — | -45.0 | 123.2 |
Net profit/loss (EUR Mn) | -153.4 | 14.5 | -259.1 | 16.6 |
EPS basic & diluted (EUR) | — | — | -3.93 | 0.25 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash, cash equivalents & financial investments (EUR Mn) | 4,703 | 4,094 | 3,684 | 3,318 | 2,998 |
Total financial debt (EUR Mn, excl. leases) | 0 | 0 | 0 | 0 | 0 |
Net debt (EUR Mn; negative = net cash) | -4,703 | -4,094 | -3,684 | -3,318 | -2,998 |
Total assets (EUR Mn) | — | — | — | — | 3,410 |
Total liabilities (EUR Mn) | — | — | — | — | 171 |
Key Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net decrease in cash & financial investments (EUR Mn) | — | -609.1 | -409.6 | -366 | -320 |
Dividends paid (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Components
| Component | EUR Mn |
|---|---|
Opening cash & financial investments (31 Dec 2025) | 2,998.0 |
Operational cash burn (incl. €78.4M return on financial investments) | -63.6 |
FX, fair-value & accrued interest effects | 38.5 |
Acquisition of equity investments | -1.1 |
Net cash from sale of subsidiaries | 4.1 |
Purchase of own shares | -2.9 |
Ouro Medicines acquisition | -733.5 |
Closing (30 Jun 2026) | 2,239.5 |
Returns & Leverage Ratios (%)
| Ratio | FY2023 | FY2024 | FY2025 | Comment |
|---|---|---|---|---|
ROE (%) | — | — | ~10† | Distorted by the non-cash deferred-income release |
ROA (%) | — | — | ~9.4† | 320.9 / ~3,410 |
ROIC | n/m | n/m | n/m | Invested capital is negative once cash is excluded |
Current ratio | — | — | very high (>10x†) | Liabilities ~€171M vs ~€3bn current assets |
Debt/equity | 0.0 | 0.0 | 0.0 | No financial debt |
Net debt/EBITDA | n/m | n/m | n/m | Net cash |
Interest coverage | n/m | n/m | n/m | Net interest income positive (€24.9M H1 2026) |
Asset turnover | n/m | n/m | n/m | — |
Cash conversion cycle | n/m | n/m | n/m | No trade working-capital model |
Revenue by counterparty location (H1 2026)
| Revenue by counterparty location (H1 2026) | EUR Mn | Share (%) |
|---|---|---|
Italy (Alfasigma, Jyseleca supply) | 14.1 | 76 |
United States (Gilead, Jyseleca royalties) | 4.5 | 24 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Euronext price (mid-Oct 2026) | ~€26.42 | MarketScreener |
Nasdaq ADS price | $29.49 (8 Oct 2026); $29.63 (6 Oct 2026) | MarketBeat; PitchBook |
Buyback execution prices | €24.78 (9–12 Jun); €25.13 avg to 30 Jun; €25.99 (28 Sep–2 Oct); €26.26 (5–9 Oct) | 6-Ks |
Shares outstanding | ~65.9M | edgar.tools |
Treasury shares | 1,877,353 (9 Oct 2026) | 6-K |
Valuation Multiples
| Multiple | Lakefront | Comment |
|---|---|---|
Market cap | ~€1.69bn† (64.0M net shares × €26.42) | — |
Enterprise value | Negative: roughly -€0.3bn to -€0.5bn† versus €1.975–2.05bn guided YE2026 cash, or versus €2.24bn at H1 | RBC also characterises EV as negative |
P/E | n/m (FY2025 EPS non-cash-driven; consensus FY2026 EPS ≈ -$1.27 per MarketBeat) | — |
EV/EBITDA, EV/Sales | n/m (negative EV) | — |
P/B | ~0.55x†, using FY2025 equity of ~€3.2bn†; post-Ouro equity lower | — |
Source Details
| Source | Rating | Avg PT | Range |
|---|---|---|---|
MarketScreener (8 analysts) | Mean "Buy" / Hold mix | €31.46 | €19.00–€44.80 |
MarketBeat | "Moderate Buy" | $37 | Morgan Stanley $26 to RBC $45 |
Analyst Conclusions
Management guidance.
-
Year-end 2026 cash and financial investments of €1.975–2.050bn, including the €50M buyback, at EUR/USD 1.175.
-
At least €1.6bn remaining after funding the portfolio to first gamgertamig approval.
-
Gamgertamig registrational studies in 2027.
-
New proof-of-concept basket studies in 2027.
-
Additional gamgertamig data later in 2026.
-
Cell-therapy wind-down substantially complete by end-Q3 2026.
[H1-2026 PR]
Consensus expectations. Negative EPS is expected through FY2027, with FY2026 EPS of about -$1.27 per share [Investing.com Q1 call coverage; MarketBeat]. Revenue is expected to stay minimal until gamgertamig royalties begin.
Bull case
-
Free option on gamgertamig. Negative EV means the market ascribes roughly zero value to an asset RBC sees generating up to $885M in peak royalties, while Gilead co-funds registration and funds all commercialisation.
-
Optionality from dry powder. At least €1.6bn of post-approval cash, plus Armed Cell milestones (up to $230M), Gilead milestones (up to $100M) and potential $75M opt-ins (×3), provide multiple non-dilutive value levers.
-
Capital return discipline. The €50M buyback below book value, with headroom up to $150M under the OLCA waiver, signals management willingness to close the discount.
Bear case
-
Single-asset, royalty-only exposure. Lakefront bears all pre-registrational risk for a 20–23% royalty that is net of KeyMed royalty sharing. A clinical stumble would leave a cash shell with a weak deal record.
-
Earnings quality. The H1 2026 profit came entirely from €123.2M of financial income against a €107.2M operating loss. A weaker USD would reverse FX gains on ~$1.96bn.
-
Governance and capital allocation history. Abandoned split, failed cell-therapy sale, €228.1M impairment, and dependence on a 25% related-party partner that retains OLCA rights over the remaining cash.
Key catalysts and monitorables (next 12 months)
Analyst verdict. Lakefront Biotherapeutics is best understood not as a biotech in the conventional sense but as a closed-end capital pool with a single, credible, partnered clinical asset attached. The company has finally put an end to five years of strategic drift. Jyseleca is gone, the discovery platform is gone, the CAR-T experiment has been written down and sold for €8M upfront, and the GLPG3667 lupus readout disappointed. In their place stands gamgertamig, a BCMAxCD3 engager with orphan and fast-track designations, a 60-plus-patient dataset, and a structure in which Gilead pays half of registration and all of commercialisation. At roughly €26 per share, the market values the equity below the €1.975–2.05bn of year-end cash management guides to. That implies investors either assign no value to gamgertamig or expect future capital misallocation to destroy part of the cash.
Both concerns are legitimate. Royalty economics of 20–23%, net of KeyMed sharing, cap the upside relative to owning the asset outright. The company's operating income is structurally negative and its reported profits are FX- and treasury-driven. The deeper question is governance. Gilead is simultaneously the largest shareholder, the commercial partner, the counterparty on the anchor deal and the holder of residual rights over most of the cash. The OLCA waiver frees only $500M for independent use.
On balance, the risk-reward is asymmetric to the upside for patient investors. The negative EV offers downside protection, upcoming gamgertamig data and a 2027 registrational start provide near-term catalysts, and buybacks below book signal alignment. We would characterise the shares as a speculative accumulate, contingent on three monitorables: data durability and safety in the late-2026 update, discipline in deploying the next €1bn-plus, and any loosening of Gilead's hold on the remaining capital. A failure on the first would turn Lakefront back into the "€3bn cash shell searching for a purpose" its critics describe.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Joined / tenure | Prior roles / background | Age |
|---|---|---|---|---|
Henry Gosebruch | Chief Executive Officer; Executive Director | CEO since 2025 (assumed role May 2025) | Industry dealmaker. Prior roles (public record): CEO of Neurogene; EVP & Chief Strategy Officer at AbbVie; investment banking (J.P. Morgan) | 53 [GlobalData] |
Aaron Cox | EVP, Chief Financial Officer | 2025 | Prior roles n/d in sources reviewed | 41 [GlobalData] |
Dan Grossman | Chief Strategy Officer | 2025 | — | — |
Eric Hedrick, MD | Chief Medical Officer | Joined Jul 2025 as clinical evaluation lead; CMO from 8 Jun 2026 | Began at Genentech; leadership roles at EQRx, BeiGene, Epizyme, Pharmacyclics; 25+ years in drug development | — |
Sooin Kwon | Chief Business Officer | — | — | — |
Tania Philipp | Chief Human Resources Officer | Appointed 5 Mar 2026 | Life-sciences HR executive with a change-management track record | — |
Ying Deng | Signatory on 6-K filings (company secretary / legal function) | — | — | — |
Board of Directors
| Director | Role | Status |
|---|---|---|
Gino Santini | Chair, Independent Non-Executive Director | Appointed Apr 2026 |
Henry Gosebruch | CEO, Executive Director | Appointed as Executive Director Apr 2026 |
Dr. Jane Griffiths | Independent Non-Executive Director | Appointed Apr 2026 |
Dawn Svoronos | Independent Non-Executive Director | Appointed Apr 2026 |
Dr. Neil Johnston | Independent Non-Executive Director | Appointed Apr 2026 |
Devang Bhuva | Non-Executive Director (Gilead-affiliated) | Appointed Apr 2026 |
Dr. Paulo Fontoura | Independent Non-Executive Director | Joined Feb 2026; resigned Jun 2026 on appointment as Global Head of R&D at Sanofi |
Board & Management Changes
| Date | Change |
|---|---|
May 2025 | Henry Gosebruch succeeds retiring CEO Paul Stoffels |
| 2025 | Aaron Cox (CFO) and Dan Grossman (CSO) join; Thad Huston (prior CFO) departs; exact date n/d |
19 Feb 2026 | Dr. Paulo Fontoura joins the board |
5 Mar 2026 | Tania Philipp appointed CHRO |
28 Apr 2026 | Board refreshed; Gino Santini becomes Chair |
8 Jun 2026 | Eric Hedrick appointed CMO |
22 Jun 2026 | Fontoura resigns (Sanofi R&D appointment) |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Gilead Therapeutics A1 Unlimited Company (Gilead Sciences) | 25.35% | 31 Dec 2025 [Mar-31-2026 6-K]; holds a subscription right allowing up to 29.9% [StockTitan Mar 2026] |
Bank of America (incl. equivalent financial instruments) | Notifiable threshold crossings (Feb–Oct 2026); exact % n/d | Transparency notices 10 & 16 Feb, 4 Mar, 8 Oct 2026 |
Madison Avenue Partners | Notifiable threshold crossing | Transparency notice 29 Jun 2026 |
Treasury shares (company) | 1,877,353 shares (~2.8%†) | 9 Oct 2026 [6-K 13 Oct 2026] |
Insider ownership | Not publicly disclosed in sources reviewed (beyond subscription rights) | — |
Competitive Landscape
Key Competitors
| Competitor | Asset(s) | Modality | Overlap with gamgertamig | Relative positioning |
|---|---|---|---|---|
Candid Therapeutics (private) | Cizutamig (BCMAxCD3), CD20xCD3 programmes | T-cell engagers | Direct: BCMAxCD3 in autoimmunity | Closest mechanistic peer; well funded |
Cullinan Therapeutics | CLN-978 (CD19xCD3) | T-cell engager | B-cell depletion in SLE, RA, Sjögren's | CD19 versus BCMA (plasma-cell coverage favours BCMA in antibody diseases) |
Merck & Co. (via Curon) | CD19xCD3 TCE | T-cell engager | Autoimmune B-cell depletion | Big-pharma resources |
Amgen | Blinatumomab and CD19 TCEs explored in autoimmunity | T-cell engager | Investigational | Leading TCE know-how |
Johnson & Johnson | Teclistamab (BCMAxCD3) in investigator autoimmune studies; nipocalimab (FcRn) | TCE / FcRn | Direct mechanism (oncology-derived) and FcRn antibody-lowering | Scale incumbent |
argenx | Efgartigimod (Vyvgart, FcRn) | FcRn antagonist | ITP, myositis, pemphigus (mixed results) | Commercial leader in FcRn |
Sanofi | Rilzabrutinib (BTKi, ITP); sutimlimab (cold agglutinin disease) | Small molecule / complement | ITP, AIHA subsets | Approved / late-stage incumbents |
Novartis | Ianalumab (anti-BAFF-R) | Antibody | ITP, Sjögren's | Late-stage |
Kyverna, Cabaletta Bio, BMS | Autologous CD19 CAR-T for autoimmunity | Cell therapy | Immune reset in myositis, SLE, etc. | Heavier treatment burden; RBC cites "recent CAR-T setbacks" |
Rigel | Fostamatinib (Tavalisse) | SYK inhibitor | ITP | Marketed |
Peer Comparison FY2025
| Metric | Lakefront (FY2025) | Cullinan (FY2024) | Kyverna (FY2024) |
|---|---|---|---|
Revenue | EUR 1112M (non-cash-driven; underlying ~EUR 43M†) | pre-revenue | pre-revenue |
Revenue growth | +304% (headline) | n/m | n/m |
Operating margin | 26.5% (headline) | n/m (loss) | n/m (loss) |
R&D intensity | — | n/m | n/m |
Net cash | ~EUR 3.0bn (FY2025); EUR 2.24bn (H1 2026) | — | — |



